about
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trialsSuccessful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation.Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma.Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.[Primary multifocal osseous Hodgkin lymphoma].Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvageA phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agentsAmplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia caseClearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid LeukemiaGenomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesCombination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyHigh-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomesSudden blastic transformation in treatment-free remission chronic myeloid leukaemiaCladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trialImpact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemiaReply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemiaIncidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitorsClonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndromeInotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl
P50
Q33435191-99ACD763-A51B-4F4A-A655-31A4087E7A7BQ34115051-021BC29A-A3FC-40EB-8CA5-A7EBF06D06F9Q35873909-CC4C0999-1513-4A42-84B8-1331871D7244Q37153527-978C7AF5-7299-4A5D-9A38-2D056BA78D16Q39051472-DB560D63-4944-4194-BB41-D9FEB061B470Q40172925-2307F497-7639-4C34-BBE9-2B15C343AAEBQ40395548-34415F88-686F-49EF-B36F-FD7B8C40A2ACQ46477192-B4007AC6-C656-437A-8888-F0F8FB0D9959Q47269765-7BA50CFB-C015-4C4D-815D-7EC3717CF58DQ57279955-C1A97596-A849-46D2-8850-5A38DABBDCAEQ57452623-18259738-5C4E-4342-8401-3F2337D05E2EQ84571512-A80A8F2C-A283-42C8-BF53-4C0AD7A1A0DFQ88493206-F789655F-94D1-4BA7-9189-A7C10BF2B9FAQ89575171-B45224E1-67A9-4D98-A0CA-488A27B4A0CFQ90012163-F8859DD2-ADDA-432A-81E8-061F20B31644Q90389938-8143D052-9FE3-436A-B924-B23D1A0D39DAQ90481499-B09EF7B1-72F8-4BDE-A681-9FD6D35FB4DCQ90986504-3DB6B234-C1C0-4A28-BDA9-7BBC0566F1B1Q91336418-68457AAE-4349-41FE-B3F8-0EA249E0D2D4Q91765734-1B2E762D-6C59-42AA-8370-51CFD215085BQ91920608-C773AB15-00FD-44AA-98F3-5807BE47BD6AQ92107014-D78BB0E5-9782-4B52-9234-9385CCA26C66Q92300110-6DA06559-4B7D-4537-8BAB-43DA6EA5111DQ93096897-60F925FF-C876-4F7D-BF96-28FD9CA2DB27
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Koji Sasaki
@ast
Koji Sasaki
@en
Koji Sasaki
@es
Koji Sasaki
@nl
type
label
Koji Sasaki
@ast
Koji Sasaki
@en
Koji Sasaki
@es
Koji Sasaki
@nl
prefLabel
Koji Sasaki
@ast
Koji Sasaki
@en
Koji Sasaki
@es
Koji Sasaki
@nl
P106
P1153
55540344900
P31
P496
0000-0002-9140-0610